We previously reported that platelets become unresponsive to agonists when stimulated in combined suspension with aspirin-treated human umbilical vein endothelial cells. Inhibition occurred concomitant with metabolism of platelet-derived endoperoxides to prostacyclin by endothelial cells. We now demonstrate that if aspirin-treated platelets which fully respond to appropriate doses of agonists are exposed to aspirin-treated endothelial cells, they remain unresponsive despite absence of prostacyclin. Platelet inhibition is due in large part to ectoADPase activity on the endothelial cells. This was established by incubating aspirin-treated endothelial cells with 14C-ADP. Radio-thin layer chromatography and aggregometry demonstrated that 14C-ADP and induction of platelet activation decreased rapidly and concurrently. AMP accumulated transiently, was further metabolized to adenosine, and deaminated to inosine. The apparent Km of the endothelial cell ADPase was 33-42 microM and the Vmax 17-43 nmol/min per 10(6) cells, values in the range of antithrombotic potential. Thus, at least three complementary systems in human endothelial cells control platelet responsiveness: a cell-associated, aspirin-insensitive ADPase which functions in parallel with fluid phase autacoids such as the aspirin-inhibitable eicosanoids, and the aspirin-insensitive endothelium-derived relaxing factor.
Introduction
Realization ofthe importance of vascular cell-cell interactions and transcellular metabolism has increased in recent years (1) . This is particularly pertinent to the case ofendothelial cells and platelets. Currently we hypothesize that endothelial cells control platelet reactivity via at least three mechanisms: a cell-associated ADPase system and two fluid phase reactants; eicosanoids such as prostacyclin (PGI2)'; and the endothelium-derived relaxing factor (EDRF). In this report we extend previous Address correspondence to Aaron J. Marcus, M.D., Thrombosis Research Laboratory, Room 13028AW, Department of Veterans Affairs Medical Center, 423 E. 23rd Street, New York, NY 10010.
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1. Abbreviations used in this paper: ASA, acetylsalicylic acid, aspirin; EC, endothelial cell(s); EDRF, endothelium-derived relaxing factor; 5-HT, serotonin, 5-hydroxytryptamine; NO, nitric oxide; PGI2, prostacyclin; PRP, platelet-rich plasma.
The Journal of Clinical Investigation, Inc. Volume 88, November 1991, 1690-1696 studies on platelet inhibition by PGI2 formed by aspirin-treated endothelial cells from platelet endoperoxides (2) . Under experimental conditions in which EDRF was not measurable, we found that platelet reactivity was inhibited by endothelial cells even though both cell types were aspirin treated and PGI2 was absent. Biochemical and functional data will be presented indicating that these aspirin-treated endothelial cells inhibit platelet function largely via a mechanism involving metabolism of ADP and consequent loss of its proaggregatory activity.
Methods
Preparation ofplatelet-rich plasma andplatelet suspensions. Blood was collected from donors -12 h after they had ingested 650 mg acetylsalicylic acid, aspirin (ASA). Platelet-rich plasma (PRP) was prepared using acid citrate-dextrose (citric acid, 38 mM; sodium citrate, 75 mM; glucose, 135 mM) as anticoagulant (3) , with an initial whole blood centrifugation at 200 g, 15 min (25°C) and a second centrifugation of the PRP (90 g, 10 min) to eliminate most of the residual erythrocytes and leukocytes. PRP was maintained at room temperature under 5% C02-air.
Platelet suspensions, when used, were prepared from PRP as described previously (3) . Final resuspension was in cold 0.15 M NaCI to a count of 1 X 10' platelets/20 Ml. The suspension was kept in a closed container at 4°C.
Preparation ofendothelial cell suspensions. Cultured human endothelial cells (P2-P8) derived from umbilical cords (4) were treated with I mM ASA (10 Ml of I M ASA in ethanol/IO ml) for 30 min at 37'C (2). Cells were washed in Hepes-buffered saline and detached with collagenase-EDTA-BSA solution (4) . An equal volume ofhuman serum-containing medium was added, the cells centrifuged at 500 g for 10 min (22'C), and finally resuspended in ASA-free buffer (0.25 ml/T-75 flask). Resuspension buffer was either Tris-Saline-Glucose (TSG) (Tris, 15 mM; NaCl, 134 mM; glucose, 5 Incubations could also be carried out with endothelial cell monolayers in multiwell plates (well capacity 1.5 ml, growth area 2 cm2; 3847; Falcon Labware, Becton Dickinson & Co., Lincoln Park, NJ), without stirring, using the same ADP concentration and total volume. Plates were secured by weights in a 37°C water bath. At indicated time intervals, supernatants were aspirated and centrifuged as above.
The well system was also used to determine the ADPase activity of fresh endothelial cells. Cells derived from two cords were pooled and divided between nine wells. Within 1-2 h of incubation, the endothelial cells were adherent. This permitted assay of EC ADPase activity free from contaminating erythrocytes, which were discarded in the supernatant.
Aggregation studies using supernatants of either thrombin-stimulated platelets or thrombin-stimulated platelet-endothelial cell mixtures as platelet agonist. Washed platelets (1 x 108) from a donor who had ingested aspirin, or platelets plus 2 X 106 ASA-treated endothelial cells were preincubated for 3 min and then stimulated with thrombin (1 U/ml), in the presence of 3 mM Ca" and 20MgM hemoglobin. Total incubation volume was 400 Ml. The microfuge tubes were incubated for 5 min after stimulation, stirring bars removed and centrifugation carried out for 10 s (Eppendorf). A control tube containing thrombin but no cells was also incubated for 5 min.
100 Ml of supernatant was rapidly transferred to an aggregometer cuvette containing 227 Ml of PRP from the same donor (1.3 X 108 platelets) and buffer (total volume ofthe assay cuvette was 500 Ml). For separation of hypoxanthine and adenosine, the solvent system consisted of 1-butanol/ethyl acetate/methanol/NH40H (7:4:3:4) (solvent 2) (7). Solvent systems were prepared at least 48 h before use and added to the tank 1 h before insertion of plates (8) Adenosine-5'-0-(2-thiodiphosphate) trilithium salt (ADP-#-S) was obtained from Boehringer Mannheim, Indianapolis, IN. Prostacyclin production was measured by RIA for 6-keto-PGF,a (DuPont-New England Nuclear).
Results
Endothelial cells inhibit platelet reactivity in totally aspirintreated systems. When ASA-treated washed platelets were stimulated by agonists in the presence of ASA-treated endothelial cells, platelet aggregation was inhibited (Fig. 1) . This occurred under conditions where control ASA-platelets alone were fully aggregated by the same quantity of stimulus (Fig. 1) . RIA measurements verified that no PGI2 had formed in these experi- ments. As shown in Fig. 2 A, PRP from a donor who had ingested aspirin was fully aggregated by 1 gM ADP. In contrast, when this PRP was stimulated in the presence of 1 X 106 ASA-EC, the inhibited aggregation curve was characterized by a brief ascending limb followed by reversal. The pattern of reversibility was reminiscent of previous experiments in this laboratory wherein ADP released from platelets by PGH2 was intentionally removed by enzymatic means (apyrase) (Fig. 2 B) Preincubation (min) Figure 3 . Time course of metabolism of (14C) ADP by aspirin-treated endothelial cell suspensions. The decrease in (14C) ADP concentration as measured by thin-layer radiochromatography (-o0 ), was accompanied by loss ofplatelet proaggregatory activity (-a-) of supernatants derived from incubation of endothelial cells with ( (Fig.  3) or monolayers (Fig. 3, inset) were employed. ADPase activity was also present on freshly adherent, but uncultured endo- (Fig. 6) . In two experiments, the Km ranged from 33 to 42 MM and the V., from 17 to 43 nmol/min per 106 cells. These / Figure 6 . Lineweaver-Burk plot relating the rate of (14C) kinetic parameters are compared in Table I with values reported in the literature for porcine aortic endothelial cells (13, 14) . Endothelial cellADPase inhibits platelet reactivity independent ofEDRF. ASA-endothelial cells (which did not produce PGI2), inhibited platelet aggregation by an aspirin-insensitive mechanism. This inhibition could have been due in part to a fluid phase reactant such as EDRF in combination with the EC ADPase activity described above. To test this possibility, known modulators of EDRF activity were added to the platelet-EC incubations. Inhibition of platelet aggregation by endothelial cells was not affected by: (a) hemoglobin or ferrous ion, which inactivate EDRF/nitric oxide (NO); (b) methylene blue, which prevents the effects of EDRF/NO by inhibiting soluble guanylate cyclase; or (c) superoxide dismutase, a potentiator of EDRF/NO via removal of superoxide radicals.
Supernatants ofEC that had been previously stimulated (15 s) with bradykinin, acetylcholine, or histamine were rapidly transferred to cuvettes containing platelets. There was little (< 10%) if any inhibition of ADP, thrombin, or collagenstimulated platelet aggregation. This indicated that the platelet inhibitory activity observed in the presence ofASA-endothelial cells was not transferable, and therefore was mainly surface associated. When endothelial cells were prestimulated with thrombin, the quantity present in the transferred supernatant served as agonist in the aggregometry cuvette. Since the same degree ofaggregation was obtained with this supernatant (even after a 3-min incubation of thrombin with EC) as with thrombin alone, nonspecific adsorption of agonist to the EC could again be ruled out as the possible etiology ofplatelet inhibition.
Release of("4C) 5-HT from stimulated platelets was used as another parameter to gauge the effects ofASA-endothelial cells on platelet reactivity. ASA-endothelial cells inhibited 5-HT release from activated platelets as well as their aggregation (Table  II) . Hemoglobin did not reverse the inhibitory effect of the ASA-endothelial cells on either 5-HT release or aggregation.
Endothelial cells reverse the capacity of thrombin-elicited platelet releasates to enhance platelet aggregation. To more closely relate the loss of thrombin-induced proaggregatory ac- tivity to EC ADPase action, the following experiments were performed. Supernatants from platelets that had been stimulated with thrombin (1 U/ml) in the absence or presence of endothelial cells were used as agonists for platelet aggregation. Curve (a) in Fig. 7 was generated by the threshold level of thrombin (0.2 U/ml) transferred from the incubation tube to the aggregometry assay cuvette. The enhanced aggregation response in curve (c) was evoked by the combined presence of transferred thrombin-induced platelet releasate in addition to transferred thrombin in the supernatant. Comparable synergy was demonstrated in control experiments in which thrombin (0.2 U/ml) plus concentrations ofADP expected to be released during the initial incubation were added directly to the aggregometer cuvette (data not shown Table I , values obtained with our human endothelial cell preparations for the apparent Km and catalytic efficiency (V. /Km) with ADP as substrate, compared favorably with those reported for porcine aortic endothelial cells (13, 14) . Calculations using these figures indicate that the quantity of ADP hydrolyzable by our endothelial cell suspensions would be sufficient to result in inhibition of platelet aggregation. For example, 0.5 X 106 EC would metabolize 2 ,M ADP to 0.8 8,M in 30 s.
In the case of agonists other than ADP, such as thrombin, collagen, and ionophore, hydrolysis of released platelet ADP may also be involved in the loss ofplatelet responsiveness (Fig.  1 , Table II ). Calculations based on results depicted in Fig. 7 indicated that enhancement ofthreshold thrombin aggregation was attributable to thrombin-released platelet ADP. Removal ofthis ADP by endothelial ecto-ADPase reversed the enhancement, and aggregation reverted to the original threshold level. This occurred in the total absence of endothelial cell PGI2 and EDRF and emphasizes the role of endothelial cell ADPases in control of platelet recruitment.
A major reason for elucidating biochemical and functional properties of endothelial cell-associated ecto-ADPases is that they can exert a significant effect on platelet reactivity independent ofthe action-of other known endothelium derived inhibitors. For evaluation of the entire known spectrum of EC control of platelet reactivity ("thromboregulation"), cell preparations which simultaneously produce PGI2, EDRF/NO, and possess ADPase activity will require additional assessment. It is also possible that as yet undefined endothelial cell thromboregulators could have contributed to results obtained by ourselves and others.
